ALLO Allogene Therapeutics Inc

$ALLO The more you look at this exceptional SSc patient from the ALLO-329 RESOLUTION trial abstract 1178 from ACR Convergence 2026, the more important the result becomes. This was progressive, treatment-refractory diffuse systemic sclerosis - a serious, high-mortality autoimmune disease - yet at only 40M ALLO-329 cells + cyclophosphamide, her mRSS dropped from 19 to 6 in just 3 months. Every time you put this patient into the proper disease context, the result tells us something important. It is still early and we need more patients and follow-up, but a 13-point reduction in clinically assessed skin thickness in progressive dcSSc deserves attention. This is one of the hardest autoimmune diseases to treat. This graphic below puts that result into perspective.

$ALLO Nice plug from Fox Business News! There guest on Making Money just had a large shoutout for ALLO. Stocks is not reacting, but he was very high on there technology! You don't see Analyst recommending $2 stocks very often!

$ALLO (1178) Preliminary Safety and Efficacy Results From a First-in-Human Phase 1 Clinical Study of ALLO-329, a Dual Anti-CD19/Anti-CD70 Allogeneic CAR T-Cell Therapy for Autoimmune Disease Monday, November 9, 2026 10:30 AM - 12:30 PM East Coast USA Time

$ALLO if 329 is positive then we go to 75. It could be a bargain of the century at 1.60. Keep moving down so I can buy more! With others failing Allo technology could be te real deal. With no ichans or CRS the big boys could be knocking on their doors if trials succeed!

$ALLO I just entered. I think at some point this thing will bounce back. Whether that's this week or next year, I wish I knew. In for the long haul.

$ALLO Short interest 118 mn as of August 31, 2026. We just need one piece of good news to send this thing not to the Moon, but straight to Mars!

$ALLO 🔥 ALLO-329 ACR abstract is now public and the early data are VERY encouraging • 9 patients treated • No DLTs • Only 1 Grade-1 CRS • B-cell suppression demonstrated • Activity at low doses • Activity even without conventional cyclophosphamide lymphodepletion 🔥 Standout result: systemic-sclerosis patient mRSS 19 → 6 at Month 3. Several individual areas reached 0, including upper arm by Day 14 and foot by Day 28. This could be a major validation signal for Allogene’s Dagger platform and the potential for off-the-shelf CAR-T with reduced/no traditional lymphodepletion. 📅 ALLO-329 ACR pres: Nov 9 🔥 TPG overhang is also GONE. TPG sold its entire 18.7M-share position at $1.55 (~$29M). Zero shares remaining. Meanwhile, ALLO has ~$424M cash/investments and runway into Q1 2029. So we have: ✅ ALLO-329 clinical activity ✅ Clean safety so far ✅ Dagger differentiation ✅ Huge cash runway ✅ TPG selling pressure finished ✅ November catalyst ✅ ALPHA3 ahead ✅ Significant short interest

$ALLO just posted fullninterview on fox, high expectations for ALLO towards the end of this year.

$ALLO for ALLO to be mentioned on FOX business I believe something is brewing. I bought more this morning I’ll keep adding in case it keep dropping

$ALLO upper trendchannel line in weekly logchart at 1.72, also have a bookmark at 1.64, which would suck ...

$ALLO On August 11, 2026, I posted that instructional holding stood at 61%. As of today, it has risen to 84.22%. Something for shorting enthusiasts to consider!

$ALLO Likely, it will slowly (and painfully) grind its way up to 2.0 before the next cycle of shorting starts; or, sky rocket based on the November announcement. Let’s see.

$ALLO Man that Fox Business mention was so weird. He mentioned all these large cap stocks and then all of a sudden talks about #ALLO. Just something weird about it.

$ALLO Has anybody ever seen a rapid reduction of mRSS like this before for a CAR-T therapy. This exceptional SSc patient shows an extremely rapid reduction in this clinical measure for SSc. Will the others in that same cohort show this rapid reduction in mRSS? Will the higher doses be even quicker? This is astonishing coming from a small allogeneic CAR-T dose. Let's hope this is the start of something very special. -sorry for the repost - had to edit my profile name and post image.

$ALLO Has anybody ever seen a rapid reduction of mRSS like this before for a CAR-T therapy. This standout SSc patient shows an extremely rapid reduction in the clinical measure SSc. Will the others in that same cohort show this rapid reduction in MRSS? Will the higher doses be even quicker? This is astonishing coming from a small allogeneic CAR-T dose. Let's hope this is the start of something very special.

$ALLO Boy they love posting on LinkedIn. I guess it's that until results in November. This is painful to watch

$ALLO The Company had $423.6 million in cash, cash equivalents, and investments as of June 30, 2026. Based on its cash, cash equivalents, and investments as of June 30, 2026, the Company currently projects its cash runway into 2029

$ALLO unbelievable how much pathetic Volume is a joke, nobody is buying and shorts are partying It can’t even move on a fckn green bio day

$ALLO Glad to have even a modest position in this. Nice bounce off recent support levels.

$ALLO serious Q - is car-t still relevant? It was the craze back w/ KITE, BLUE, JUNO like in 2016-2017. Now a days theres "cancer vaccines", gene editing and a bunch of other stuff I have no clue about. Tldr, is there a light at the end of this tunnel?